BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer & Founder
Vincent O'Neill - Executive Vice President, Chief of Product Development and Medical Officer
Richard Steinhart - Senior Vice President and Chief Financial Officer
Matt Wiley - Senior Vice President and Chief Commercial Officer
Conference Call Participants
Sumant Kulkarni - Canaccord Genuity
Raghuram Selvaraju - H.C. Wainwright
Operator
Good morning, and welcome to the BioXcel Therapeutics Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. After the formal remarks, there will be a question-and-answer session. [Operator Instructions].
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.
Risk factors that may affect future results are detailed in the company's annual report on Form 10-K for the year ended December 31, 2023, which can be found at www.bioxceltherapeutics.com or on www.sec.gov and which will be updated in its quarterly report on Form 10-Q for the quarterly period ended June 30, 2024.
As a reminder, today's call is being recorded. Speaking on today's call are Dr. Vimal Mehta, Chief Executive Officer; Dr. Vince O'Neill, Chief of Product Development and Medical Officer; and Richard Steinhart, Chief Financial Officer.
They will be joined in the question-and-answer session by Dr. Frank Yocca, Chief Scientific Officer; Matt Wiley, Chief Commercial Officer; and Dr. Rob Risinger, Chief Medical Officer of Neuroscience.
It is now my pleasure to turn the call over to Dr. Mehta. Please go ahead.
Vimal Mehta
Thank you, operator. Good morning, and thank you for joining us today. At BioXcel Therapeutics, we are focused on expanding our lead asset, BXCL501, into the home setting for bipolar and schizophrenia-related agitation, and into a new indication for Alzheimer's-related agitation.
We are extremely passionate and motivated to bring this much needed therapeutic option to millions of patients who are struggling with episodes of agitation. We believe BXCL501 offers a compelling value proposition, and we look forward to advancing the development of our two clinical programs.
At this time, we are delighted to reach an important juncture with the SERENITY program as we are finalizing development plans for BXCL501 in the at-home setting, where the majority of agitation episodes occur. We truly believe that this is a much needed treatment option for patients, caregivers, and health care providers as there are no FDA-approved therapies for agitation in the home setting. The SERENITY At-Home trial could represent a near-term value creation opportunity to potentially expand beyond the institutional setting where IGALMI is currently marketed.